Registered business · FR · Founded 2020 · Accounts through 2023 · Updated Jul 27, 2026
See what is holding the value back today, what this company could be worth in five years and which actions make the difference. The estimate is based on filed annual accounts.
Is this your company? Claim and manage this profile
Historical rounded range based on the latest available public filing for fiscal year 2023. This is not a current market value or asking price.
Based on filed company accountsThe historical valuation curve is public. Create a free account for the future five-year growth forecast, the insights behind it, and concrete action points that can increase this company’s value.
Free account · private workspace
Public filings are a starting point. Owner-confirmed accounts, net debt, leases and commercial context can refine the range for a sale, financing or transfer.
You have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
Register your interest privately. Upswitch reviews every request and keeps it queued until a safe, verified owner contact route is available.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Claim this companyOperating as a business in NACE sector 81.21, MEDIPREST is registered in France. The company was founded in 2020.
MEDIPREST is listed in French National Business Register (RNE/INPI) under registry number 891191405. The public employee band is 03, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Within the French NACE 81.21 cluster, public-record data is filed annually via the national company registry.
Across the 2021-2023 window revenue has more than doubled, moving from €304,411 to €538,342.
The most recent annual filing covers 2023 (period end 2023-12-31).
The historical indicative range for MEDIPREST is refreshed when new regulator-filed data becomes available; until then it remains a filing-year research aid, not a current market value.
Public regulator-filed figures across 2 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202331 Dec 2023 | €538,342 | - | €145,809 | €95,261 | - |
| 202131 Dec 2021 | €304,411 | - | €92,660 | €13,687 | - |
MEDIPREST was founded in 2020 and is registered with French National Business Register (RNE/INPI).
MEDIPREST is registered under NACE 81.21. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2023 (period end 2023-12-31), publicly available via French National Business Register (RNE/INPI).
This page shows a rounded historical indicative range for MEDIPREST, based on the latest available public filing for fiscal year 2023. It is not a current market value, asking price, certified or statutory valuation, or financial, investment, tax or legal advice. Verify current figures before relying on it for any decision or transaction.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
Indicative public valuation range based on financial year 2023. This historical record does not yet contain an immutable calculation snapshot, so no sector range is reconstructed after the fact. Not a transaction value, asking price or fairness opinion.
